Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

Efficacy and Safety of Pegylated-interferonα-2a Plus Entecavir in HBeAg Positive Chronic Hepatitis B Patients

REN Chengjian;XIONG Yanfei;Clinical Liver Disease Research Center,the Third People’s Hospital of Yongzhou City,Hu’nan Province;  
Objective:To investigate the efficacy of a 96-week course of Peg-IFNα-2a and entecavir(ETV)combination therapy for achieving seroconvesion at 24 weeks after completion in patients with chronic hepatitis B(CHB).Methods:A total of 165 CHB patients with positivity for hepatitis B e antigen(HBeAg)were randomly divided into two groups(A,B).67 patients in group A were treated with Peg-IFNα-2aand ETV.89 patients in group B were treated with ETV.All patients were treated for rates of conversion to HBV DNA negative status,alanine aminotransferase(ALT)normalization,HBeAg and HBsAg seroconversion.Results:The rates of HBeAg serconversion were significantly different between the two groups at treatment weeks 48,72 and 96,at 24 weeks after treatment completion,all P0.01.The rates of HBsAg serconversion were significantly different between the two groups at 48weeks(P0.05),the rates of HBsAg serconversion were significantly different between the two groups at treatment weeks 72 and 96,at 24 weeks after treatment completion,all P0.01.Conclusion:Prolonged Peg-IFNα-2aplus ETV combination therapy can significantly improve the rates of HBeAg and HBsAg seroconversion in HBeAg positive CHB patients.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved